Treating irrtable bowel syndrome or disease
AssigneeMeracol Corporation Limited
InventorsTimothy David Meakin, Dianne Cadwallader, Craig Leonard Heatley
Life of this patent
Estimating the term…
Abstract
The treatment of humans or other mammals for irritable bowel syndrome (IBS) or irritable bowel disease (IBD) using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.
Claims31
A method of treatment and/or prophylaxis of a mammal for irritable bowel syndrome and/or for irritable bowel disease which comprises or includes administering or having self administered to such mammal an effective amount of either
- (a) cetyl myristate, or
- (b) cetyl myristate and cetyl palmitate.
A method of any one of the preceding claims wherein said effective amount of (a) or (b) is by means of one or more capsules.
A method of any one of the preceding claims where said mammal is a human being suffering from irritable bowel syndrome and the administration is for treatment purposes.
A method of any one of the preceding claims where both cetyl myristate and cetyl palmitate in admixture are administered, the ratio by weight to weight being 95:5 respectively.
A method of treatment of a human being for irritable bowel syndrome which comprises or includes having administered to that human an effective amount of cetyl myristate.
A method of treatment of a human being for irritable bowel disease which comprises or includes having administered to that human an effective amount of cetyl myristate.
An oral pharmaceutical composition for treating irritable bowel syndrome which comprises or includes both cetyl myristate and cetyl palmitate.
An oral pharmaceutical composition for treating irritable bowel disease which comprises or includes both cetyl myristate and cetyl palmitate.
And oral dosage unit effective in the treatment of irritable bowel syndrome and/or irritable bowel disease, said dosage unit having either
- (a) cetyl myristate, or
- (b) a mixture of cetyl myristate and cetyl palmitate.
The use, in the manufacture of oral dosage units for the treatment or prophylaxis of irritable bowel disease in a mammal, of
- (a) cetyl myristate, or
- (b) a mixture of cetyl myristate and cetyl palmitate, or
- (c) cetyl palmitate.
The use, in the manufacture of oral dosage units for the treatment or prophylaxis of irritable bowel syndrome in a mammal, of
- (a) cetyl myristate or
- (b) cetyl myristate and cetyl palmitate or
- (c) cetyl palmitate.
Dependencies are inferred from the claim text.